Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 34Terminated 11Unknown 9Active not recruiting 5Recruiting 4Withdrawn 3Not yet recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Specimen Handling 3Biopsy 3venetoclax 2selinexor 2luspatercept 2Tacrolimus 2Lymphatic Irradiation 2Imatinib Mesylate 2Busulfan 2Azacitidine 2trametinib 1tagraxofusp 1peginterferon alfa-2b 1olutasidenib 1nilotinib 1flumatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1dabrafenib 1Tyrosine Kinase Inhibitors 1Thiotepa 1Spectroscopy, Near-Infrared 1Sirolimus 1Single-Cell Gene Expression Analysis 1Resistance Training 1Receptors, Antigen, T-Cell 1Quality of Life 1Pleurodesis 1Phlebotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Dasatinib × Myeloid × Clear all
NCT07269470 2026-05-05

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡